Does the aldosterone: renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study
2007

Study on Aldosterone: Renin Ratio and Hypertension Treatment

Sample size: 120 publication Evidence: moderate

Author Information

Author(s): Parthasarathy Hari K, Alhashmi Khamis, McMahon Alex D, Struthers Allan D, Connell John MC, McInnes Gordon T, Ford Ian, MacDonald Thomas M

Primary Institution: University of Dundee

Hypothesis

Does the aldosterone: renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension?

Conclusion

The study aims to determine if the aldosterone: renin ratio can predict better blood pressure control with spironolactone compared to bendroflumethiazide in hypertensive patients.

Supporting Evidence

  • The study will include 120 hypertensive subjects.
  • It aims to compare the effects of spironolactone and bendroflumethiazide on blood pressure.
  • Randomisation will be stratified by aldosterone: renin ratio.

Takeaway

This study is trying to find out if a specific blood test can help doctors choose the best medicine for people with high blood pressure.

Methodology

A double-blind, randomised, crossover, controlled trial comparing spironolactone and bendroflumethiazide over 12 weeks each, with a 2-week washout period.

Potential Biases

Potential bias from including patients already on medication, which may affect the generalizability of the results.

Limitations

The study may be biased towards a secondary care population due to the inclusion of patients already on antihypertensive therapy.

Participant Demographics

Hypertensive subjects with varying aldosterone: renin ratios.

Statistical Information

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2261-7-14

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication